Newfeed

BOE is conducting trials using Omniply’s technology BEIJING and MONTREAL, Oct. 22, 2024 /PRNewswire/ — BOE Technology Group Co. LTD (BOE), a global leader in the semiconductor display industry and Omniply Technologies the creator of flexible sticker electronics, today announced that the

225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical developmentSatoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clin

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: